Humanigen — Technical Presentation (August 2021)
13 slides from Humanigen's technical presentation, Aug 4, 2021
Slide 1: LIVE-AIR Phase 3 Study Update: Highest Response Rates Observed in Black and African-American Patients
Confidential LIVE - AIR Phase 3 Study Update: Highest Response Rates Observed in Black and African - American Patients August 2021
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation are forward - looking statements . Forward - looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding f
Slide 3: Summary
3 Summary • Hyper - vulnerable to COVID - 19 • Vaccine hesitancy, underlying medical conditions, socioeconomic factors • 13% of the population and 23% of COVID - 19 deaths 1 • Hyper - responders to lenzilumab treatment • In Black/African - American overall, 2.7x increase in survival without ventilat
Slide 4: Reasons Why African-Americans are Disproportionately Affected by COVID-19
4 Reasons Why African - Americans are Disproportionately Affected by COVID - 19 • 36% vaccinated • Lowest among all groups • Vaccine hesitancy • Historical mistrust of healthcare and Government system Vaccination Rates • Higher incidence and prevalence of chronic illnesses e.g., diabetes • Associate
Slide 5: Black American Vaccination Lowest by Race/Ethnicity
5 Black American Vaccination Lowest by Race/Ethnicity 1 1. Kaiser Family Foundation, https://www.kff.org/coronavirus - covid - 19/issue - brief/latest - data - on - covid - 19 - vaccinations - race - ethnici ty/, July 21, 2021 Percent of total Population with at Least One COVID - 19 Vaccine Dose by
Slide 6: LIVE-AIR: Lenzilumab Phase 3 Randomized, Double-blind, Placebo-controlled Study Design
6 LIVE - AIR: Lenzilumab Phase 3 Randomized , Double - blind, Placebo - controlled Study Design Early intervention with lenzilumab, in addition to current standard of care, to prevent and treat CS and prevent progression to IMV and/or death • Randomized , double - blind, placebo - controlled, multi
Slide 7: Black and African-Americans Well Represented in LIVE-AIR Patient Population
7 Black and African - Americans Well Represented in LIVE - AIR Patient Population 1 60.1 18.5 13.4 5.9 1.3 0.8 43.2 38.5 14.8 1.9 0.5 1.1 0 10 20 30 40 50 60 70 White (non- hispanic) Hispanic Black/African American Asian American Indian/Alaskan native other % LIVE - AIR Diversity Compared with US Ce
Slide 8: Primary Endpoint met: Survival without Ventilation (SWOV)
8 Primary Endpoint met: Survival without Ventilation (“SWOV”) 8 Patients who died or required ventilation K - M Estimate Population Lenzilumab Placebo Lenzilumab vs placebo hazard ratio (95% CI) P value mITT (n=479) 15.6% (11.5 – 20.9) (n=236) 22.1% (17.4 – 27.9) (n=243) 1.54 (1.02 – 2.32) 0.0403 Tr
Slide 9: SWOV in All Patients with Baseline CRP < 150
9 SWOV in All Patients with Baseline CRP < 150* 9 Patients who died or required ventilation K - M Estimate Population Lenzilumab (95% CI) Placebo (95% CI) Lenzilumab vs placebo hazard ratio (95% CI) P value (n=351) 9.8% (6.1 - 15.4) (n=168) 21.2% (15.9 - 27.9) (n=183) 2.54 (1.46 – 4.41) 0.0009 *C -
Slide 10: Black/African-American population with Baseline CRP < 50
10 Black/African - American population with Baseline CRP < 150* 10 For Black/African - American Patients, treatment with lenzilumab resulted in a 9x Increase in the likelihood of surviving and without needing to be on mechanical ventilation Lenzilumab is being developed as a potential treatment for
Slide 11: Black/African-American Patients had a 9-fold increase in the likelihood of Survival without ventilation
11 Black/African - American Patients had a 9 - fold increase in the likelihood of Survival without ventilation 11 Lenzilumab is being developed as a potential treatment for COVID - 19, it is not currently authorized or approved for use in any c ountry
Slide 12: COVID-19 treatment landscape by patient reach and disease severity
12 Patient Reach Disease Severity Anti - viral Antibodies Outpatient Antiviral Immuno - Modulators COVID - 19 Vaccines Prophylaxis Critical patients in the ICU on mechanical ventilation and progressing rapidly 2,6,7 IMV – 2020: ~294K, 2021: ~349K, 2025: ~192K Bamlanivimab + Etesevimab Casirivimab +
Slide 13: Conclusion
13 Conclusion • Higher infection rates • Higher hospitalization rates • Higher death rates Black and African Americans are disproportionately affected by COVID - 19 1 • Systemic disparities • Social determinants of health • Low vaccination rates Multiple potential reasons for this 1, 2 • 9x Increase